1. Kohler S., Kerl H. Neural tumors. WHO Classification of tumours 2006(6): 272.

2. Lanoy E., Costagliola D., Engels E.A. Skin cancers associated with HIV infection and solid-organ transplantation among elderly adults. Int J Cancer 2010; 126(7): 1724 - 31.

3. Lanoy E., Dores G.M., Madeleine M.M. et al. Epidemiology of nonkeratinocytic skin cancers among persons with AIDS in the United States. AIDS 2009; 23(3): 385 - 93.

4. Koljonen V., Kukko H., Tukiainen E. et al. Incidence of Merkel cell carcinoma in renal transplant recipients. Nephrol Dial Transplant 2009; 24(10): 3231 - 5.

5. Lunder E.J., Stern R.S. Merkel-cell carcinomas in patients treated with methoxsalen and ultraviolet A radiation. N Engl J Med 1998; 339: 1247 - 8.

6. Popp S., Waltering S., Herbst C. et al. Uv-b-type mutations and chromosomal imbalances indicate common pathways for the development of merkel and skin squamous cell carcinomas. Int J Cancer 2002; 99: 352 - 60.

7. Feng H., Shuda M., Chang Y., Moore P. Clonal integration of a polyomavirus in human Merkel cell carcinoma. Sience 2008; 319: 1096 - 100.

8. Киселев Ф.Л., Имянитов Е.Н., Киселева Н.П., Левина Е.С. Молекулярная онкология: от вирусной теории к лечению рака. М.: ГЕОС, 2013. С. 38 - 40.

9. Rollison D.E., Giuliano A.R., Becker J.C. New virus associated with merkel cell carcinoma development. J Natl Compr Canc Netw 2010; 8: 874 - 80.

10. Amber K., McLeod M.P., Nouri K. The Merkel cell polyomavirus and its involvement in Merkel cell carcinoma. Dermatol Surg 2013; 39: 232 - 8.

11. Tilling T., Moll I. Which are the cells of origin in merkel cell carcinoma? J Skin Cancer 2012; 2012: 680410. DOI: 10.1155/2012/680410.

12. Schwartz R.A. Skin Cancer. Recognition and Management. 2^nd edn. N 13, 2008. Pp. 220 - 225.

13. IMMOMEC (European Commission). Merkel cell carcinoma. Available at: http://www.immomec.eu/project/objectives/background/merkel-cell-carcinoma. Last accessed April 2015.

14. van der Zwan J.M., Trama A., Otter R. et al. Rare neuroendocrine tumours: results of the surveillance of rare cancers in Europe project. Eur J Cancer 2013; 49(11): 2565e78.

15. Paulson K.G., Park S.Y., Vandeven N.A. et al. Merkel cell carcinoma: Current US incidence and projected increases based on changing demographics. J Am Acad Dermatol 2018; 78(3): 457-63.e2. DOI: 10.1016/j.jaad.2017.10.028.

16. Brierley J.D., Gospodarowicz M.K., Wittekind C. (eds.). Merkel Cell Carcinoma of Skin. In: TNM Classification of Malignant Tumours. 8^th edn. Oxford, UK: Wiley-Blackwell, 2017.

17. Edge S., Byrd D., Compton C.C. et al. Merkel cell carcinoma. AJCC Cancer Staging Manual. 7^th edn., 2010, Pp. 315 - 323.

18. Sobin L., Gospodarowicz M., Wittekind C. Merkel cell carcinoma. TNM Classification of Malignant Tumours. 7^th edn.

19. Chen K.T., Papavasiliou P., Edwards K. et al. A better prognosis for Merkel cell carcinoma of unknown primary origin. Am J Surg 2013; 206(5): 752 - 7. DOI: 10.1016/j.amjsurg.2013.02.005.

20. Foote M., Veness M., Zarate D. Poulsen M Merkel cell carcinoma: the prognostic implications of an occult primary in stage IIIB (nodal) disease. J Am Acad Dermatol. 2012; 67(3): 395 - 9. DOI: 10.1016/j.jaad.2011.09.009.

21. Tarantola T.I., Vallow L.A., Halyard M.Y. et al Unknown primary Merkel cell carcinoma: 23 new cases and a review. J Am Acad Dermatol 2013; 68(3): 433 - 40. DOI: 10.1016/j.jaad.2012.07.035.

22. Heath M., Jaimes N., Lemos B. et al. Clinical characteristics of Merkel cell carcinoma at diagnosis in 195 patients: the "AEIOU" features. J Am Acad Dermatol 2008; 58: 375 - 81.

23. G. Taylor, D.K. Mollick, E.R. Heilman. Merkel Cell Carcinoma. D.S. Rigel, R.J. Friedman, L.M. Dzubow, D.S. Reintgen, J. Bystryn, R. Marks (Eds.), Cancer of the Skin, Elsevier Saunders, Philadelphia, PA (2005), pp. 323 - 327.

24. Aron M., Zhou M. Merkel cell carcinoma of the genitourinary tract. Arch Pathol Lab Med 2011; 135(8): 1067 - 71. DOI: 10.5858/2010-0072-RSR2.

25. Орлова К.В. Изучение клинико-морфологических и молекулярно-биологических аспектов карциномы Меркеля. Дис. ... канд. мед. наук, 2015. С. 49 - 51.

26. Bichakjian C.K., Lowe L., Lao C.D. et al. Merkel cell carcinoma: critical review with guidelines for multidisciplinary management. Cancer 2007; 110: 1 - 12.

27. Schmults C.D. et al. Merkel cell carcinoma. NCCN Clinical practice guidelines in oncology 2019; (2).

28. Koljonen V., Kukko H., Tukiainen E. Second cancers following the diagnosis of Merkel cell carcinoma: a nationwide cohort study. Cancer Epidemiol 2010; 34: 62 - 5.

29. Reichgelt B.A., Visser O. Epidemiology and survival of Merkel cell carcinoma in the Netherlands. A population-based study of 808 cases in 1993 - 2007. Eur J Cancer 2011; 47: 579 - 85.

30. Effekhari F., Wallace S., Silva E.G., Lenzi R. Merkel cell carcinoma of the skin: imaging and clinical features in 93 cases. Br J Radiol 1996; 69: 226 - 33.

31. Medina-Franco H., Urist M.M., Fiveash J. Multimodality treatment of Merkel cell carcinoma: case series and literature review of 1024 cases. Ann Surg Oncol 2001; 8: 204 - 8.

32. Schwartz J.L., Bichakjian C.K., Lowe L. Clinicopathologic features of primary Merkel cell carcinoma: a detailed descriptive analysis of a large contemporary cohort. Dermatol Surg 2013; 39: 1009 - 16.

33. Brenner B., Sulkes A., Rakowsky E. Second neoplasms in Merkel cell carcinoma. Am J Clin Oncol 2002; 91: 1358 - 62.

34. Bzhalava D., Bray F., Storm H., Dilner J. Risk of second cancers after the diagnosis of Merkel cell carcinoma in Scandinavia. Br J Cancer 2011; 104: 178 - 80.

35. Edlich R.F. et al. Excisional biopsy of skin tumors. J Long Term Eff Med Implants. 2004; 14(3): 201 - 14.

36. Pflugfelder A., Weide B., Eigentler T.K. et al. Incisional biopsy and melanoma prognosis: facts and controversies. Clin Dermatol 2010; 28: 316 - 8.

37. Lebbe C. et al. Diagnosis and treatment of Merkel cell carcinoma. European consensus-based interdisciplinary guideline. Eur J Cancer. 2015; 51(16): 2396 - 403.

38. Elston A.M. et al. Skin biopsy. Biopsy issues in specific diseases. J Am Acad Dermatol. 2016 (74); 1 - 16.

39. Rayess H.M., Gupta A., Svider P.F. et al. A critical analysis of melanoma malpractice litigation: Should we biopsy everything? Laryngoscope 2017; 127(1): 134-9. DOI: 10.1002/lary.26167.

40. Seiverling E.V. et al. Biopsies for skin cancer detection: dispelling the myths. J Fam Pract. 2018 May; 67(5): 270 - 274.

41. Bolshinsky V., Lin M.J., Serpell J. et al. Frequency of residual melanoma in wide local excision (WLE) specimens after complete excisional biopsy. J Am Acad Dermatol 2016; 74(1): 102 - 7. DOI: 10.1016/j.jaad.2015.08.065.

42. Luk P.P., Vilain R., Crainic O. et al. Punch biopsy of melanoma causing tumour cell implantation: another peril of utilising partial biopsies for melanocytic tumours. Australas J Dermatol 2015; 56(3): 227 - 31. DOI: 10.1111/ajd.12333.

43. Kumar A. et al. Profile of skin biopsies and patterns of skin cancer in a tertiary care center of Western Nepal. Asian Pac J Cancer Prev. 2015; 16(8): 3403 - 6.

44. Becker J.C. Merkel cell carcinoma. Ann Oncol 2010; 21 Suppl 7: vii81-5.

45. Schneider S., Thurnher D., Erovic B.M. Merkel cell carcinoma: interdisciplinary management of a rare disease. J Skin Cancer 2013; 2013: 189342.

46. Harms K.L., Healy M.A., Nghiem P. Analysis of prognostic factors from 9387 Merkel cell carcinoma cases forms the basis for the new 8^th Edition AJCC Staging System. Ann Surg Oncol 2016; 23: 3564 - 71.

47. Siva S., Byrne K., Seel M. et al. 18F-FDG PET provides high-impact and powerful prognostic stratification in the staging of Merkel cell carcinoma: a 15-year institutional experience. J Nucl Med 2013; 54(8): 1223 - 9.

48. Hawryluk E.B., O'Regan K.N., Sheehy N. et al. Positron emission tomography/computed tomography imaging in Merkel cell carcinoma: a study of 270 scans in 97 patients at the Dana-Farber/Brigham and Women's Cancer Center. J Am Acad Dermatol 2013; 68: 592 - 9.

49. Santamaria-Barria J.A., Boland G.M., Yeap B.Y. et al. Merkel cell carcinoma: 30-year experience from a single institution. Ann Surg Oncol 2013; 20: 1365 - 73.

50. Enzenhofer E., Ubl P., Czerny C., Boban M.E. Imaging in Merkel cell carcinoma. J Skin Cancer 2013; 2013: 973123.

51. Honeybul S. Cerebral metastases from Merkel cell carcinoma: long-term survival. J Surg Case Rep 2016; 2016(10).

52. Nguyen B.D., McCullough A.E. Imaging of Merkel cell carcinoma. Radio Graphics 22(2).

53. Abul-Kasim K., Soderstrom K., Hallsten L. Extensive central nervous system involvement in Merkel cell carcinoma: a case report and review of the literature. J Med Case Rep 2011; 5: 35.

54. Mills J.K., White I., Diggs B. et al. Effect of biopsy type on outcomes in the treatment of primary cutaneous melanoma. Am J Surg 2013; 205(5): 585 - 90. DOI: 10.1016/j.amjsurg.2013.01.023.

55. Coit D.G., Thompson J.A., Albertini M. et al. NCCN Clinical Practice Guidelines in Oncology. Melanoma. Version 3.2018: National Comprehensive Cancer Network, Inc; 2018. Available at: https://www.nccn.org/professionals/physician_gls/pdf/melanoma_blocks.pdf.

56. DeMay R.M. Merkel cell carcinoma. The art and science of cytopathology, 2^nd edn., 2012. P. 717.

57. Rao P., Balzer B.L., Lemos B.D. et al. Protocol for the examination of specimens from patients with Merkel cell carcinoma of the skin. Arch Pathol Lab Med 2010; 134: 341 - 4.

58. Bobos M., Hytiroglou P., Kostopoulos I. et al. Immunohistochemical distinction between Merkel cell carcinoma and small cell carcinoma of the lung. Am J Dermatopathol 2006; 28(2): 99 - 104.

59. Warner T.F., Uno H., Hafez G.R. Merkel cells and Merkel cell tumors. Ultrastructure, immunocytochemistry and review of the literature. Cancer 1983; 52: 238 - 45.

60. Jensen K., Kohler S., Rouse R.V. Cytokeratin staining in Merkel cell carcinoma: an immunohistochemical study of cytokeratins 5/6, 7, 17, and 20. Appl Immunohistochem Mol Morphol 2000; 8(4): 310 - 5.

61. Pulitzer M.P., Brannon A.R., Berger M.F. Cutaneous squamous and neuroendocrine carcinoma: genetically and immunohistochemically different from Merkel cell carcinoma. Mod Pathol 2015; 28: 1023 - 32.

62. Mott R.T., Smoller B.R., Morgan M.B. Merkel cell carcinoma: a clinicopathologic study with prognostic implications. J Cutan Pathol 2004; 31: 217 - 23.

63. Smoller B.N., Bichakjian C.K., Brown J.A. Protocol for the examination of specimens from patients with Merkel cell carcinoma of the skin, version 4.0.0.1. College of American Pathologists cancer protocol templates 2017.

64. Andea A.A., Coit D.G., Amin B., Busam K.J. Merkel cell carcinoma: histologic features and prognosis. Cancer 2008; 113: 2549 - 58.

65. Scott M.P., Helm K.F. Cytokeratin 20: a marker for diagnosing Merkel cell carcinoma. Am J Dermatopathol 1999; 21: 16 - 20.

66. Hanly A.J., Elgart G.W., Jorda M. et al. Analysis of thyroid transcription factor-1 and cytokeratin 20 separates Merkel cell carcinoma from small cell carcinoma of lung. J Cutan Pathol 2000; 27: 118 - 20.

67. Hanly A.J., Elgart G.W., Jorda M. Analysis of thyroid transcription factor-1 and cytokeratin 20 separates Merkel cell carcinomas from other small cell carcinomas. Am J Surg Pathol 2000; 24: 1217 - 23.

68. Treglia G., Dabbagh Kakhki V.R., Giovanella L., Sadeghi R. Diagnostic performance of fluorine-18-fluorodeoxyglucose positron emission tomography in patients with Merkel cell carcinoma: a systematic review and meta-analysis. Am J Clin Dermatol 2013; 14(6): 437 - 47.

69. Schmalbach C.E., Lowe L., Teknos T.N. et al. Reliability of sentinel lymph node biopsy for regional staging of head and neck Merkel cell carcinoma. Arch Otolaryngol Head Neck Surg 2005; 131: 610 - 4.

70. Gupta S.G., Wang L.C., Penas P.F. et al. Sentinel lymph node biopsy for evaluation and treatment of patients with Merkel cell carcinoma: The Dana-Farber experience and meta-analysis of the literature. Arch Dermatol 2006; 142: 685 - 90.

71. Allen P.J., Busam K., Hill A.D. et al. Immunohistochemical analysis of sentinel lymph nodes from patients with Merkel cell carcinoma. Cancer 2001; 92: 1650 - 5.

72. Su L.D., Lowe L., Bradford C.R. et al. Immunostaining for cytokeratin 20 improves detection of micrometastatic Merkel cell carcinoma in sentinel lymph nodes. J Am Acad Dermatol 2002; 46: 661 - 6.

73. Allen P.J., Zhang Z.F., Coit D.G. Surgical management of Merkel cell carcinoma. Ann Surg 1999; 229: 97 - 105.

74. Tai P. A practical update of surgical management of Merkel cell carcinoma of the skin. ISRN Surg 2013; 2013: 850797.

75. Wringht G.P., Holtzman M.P. Surgical resection improves median overall survival with marginal improvement in long-term survival when compared with definitive radiotherapy in Merkel cell carcinoma: a propensity score matched analysis of the National Cancer Database. Am J Surg 2018; 215: 384 - 7.

76. Haymerte G., Fochtmann A., Kunstfeld R. Merkel cell carcinoma: overall survival after open biopsy versus wide local excision. Head and Neck 2016; 38 (Suppl 1): E1014-8.

77. Singh B., Qureshi M.M., Truong M.T., Sahni D. Demographics and outcomes of stage I-II Merkel cell carcinoma treated with Mohs micrographic surgery compared with wide local excision in the National Cancer Data Base. J Am Dermatol 2018.

78. Kim J.A., Choi A.H. Effect of radiation therapy on survival in patients with resected Merkel cell carcinoma: a propensity score surveillance, epidemiology, and end results database analysis. JAMA Dermatol 2013; 149: 831 - 8.

79. Mojica P., Smith D., Ellenhorn J.D. Adjuvant radiation therapy is associated with improved survival in Merkel cell carcinoma of the skin. J Clin Oncol 2007; 25: 1043 - 7.

80. Rush Z., Fields R.C., Lee N., Brownell I. Radiation therapy in the management of Merkel cell carcinoma: current perspectives. Expert Rev Dermatol 2011; 6: 395 - 404.

81. Lewis K.G., Weinstock M.A., Weaver A.L., Otley C.C. Adjuvant local irradiation for Merkel cell carcinoma. Arch Dermatol 2006; 142: 693 - 700.

82. Jouary T., Leyral C., Dreno B. et al. Adjuvant prophylactic regional radiotherapy versus observation in stage I Merkel cell carcinoma: a multicentric prospective randomized study. Ann Oncol 2012; 23: 1074 - 80.

83. Voog E., Biron P., Martin J.P., Blay J.Y. Chemotherapy for patients with locally advanced or metastatic Merkel cell carcinoma. Cancer 1999; 85: 2589 - 95.

84. Cowey C.L., Mahnke L., Espirito J. et al. Real-world treatment outcomes in patients with metastatic Merkel cell carcinoma treated with chemotherapy in the USA. Future Oncol 2017; 13(19): 1699 - 710.

85. Iyer J.G., Blom A., Doumani R. et al. Response rates and durability of chemotherapy among 62 patients with metastatic Merkel cell carcinoma. Cancer Med 2016; 5(9): 2294 - 301.

86. Wright G.P., Holtzman M.P. Surgical resection improves median overall survival with marginal improvement in lonh-term survival whan compared with definitive radiotherapy in Merkel cell carcinoma: a propensuty score matched analysis of the National Cancer Database. Am J Surg 2018; 215: 384 - 7.

87. Oken M.M., Creech R.H., Tormey D.C. et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5(6): 649 - 55.

88. Simmons C., McMillan D.C., Tuck S. et al. "How Long Have I Got?" - A Prospective Cohort Study Comparing Validated Prognostic Factors for Use in Patients with Advanced Cancer. Oncologist 2019.

89. Tai P.T., Yu E., Winquist E. et al. Chemotherapy in neuroendocrine/Merkel cell carcinoma of the skin: case series and review of 204 cases. J Clin Oncol 2000; 18: 2493 - 9.

90. Pectasides D., Pectasides M., Psyrri A. et al. Cisplatin-based chemotherapy for Merkel cell carcinoma of the skin. Cancer Invest 2006; 24: 780 - 5.

91. Desch L., Kunstfeld R. Merkel cell carcinoma: chemotherapy and emerging new therapeutic options. J Skin Cancer 2013; 2013: 327150.

92. Schadendorf D., Lebbe C., Zur Hausen A. et al. Merkel cell carcinoma: epidemiology, prognosis, therapy and unmet medical needs. Eur J Cancer 2017; 71: 53 - 69. DOI: 10.1016/j.ejca.2016.10.022.

93. Nghiem P., Kaufman H.L., Bharmal M. et al. Systematic literature review of efficacy, safety and tolerability outcomes of chemotherapy regimens in patients with metastatic Merkel cell carcinoma. Future Oncol 2017; 13(14): 1263 - 79.

94. Sharma D., Flora G., Grunberg S.M. Chemotherapy of metastatic Merkel cell carcinoma: case report and review of the literature. Am J Clin Oncol 1991; 14(2): 166 - 9.

95. Pectasides D., Moutzourides G., Dimitriadis M. Chemotherapy for Merkel cell carcinoma with carboplatin and etoposide. Am J Clin Oncol 1995; 18(5): 418 - 20.

96. Yildiz F., Buyuksimsek M., Sakalar T. et al. Merkel cell carcinoma in Turkey: a multicentric study. J Clin Oncol 2018; 36(15_suppl): e21591.

97. Viola G., Visca P., Bucher S., Migliano E. Merkel cell carcinoma (CAV chemotherapy). Clin Ter 2006; 157(6): 553 - 9.

98. Hanna N., Bunn P.A., Langer C. et al. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small cell lung cancer. J Clin Oncol 2006; 24(13): 2038 - 43.

99. Lipson E.J., Vincent J.G., Loyo M. et al. PD-L1 expression in the Merkel cell carcinoma microenvironment: association with inflammation, Merkel cell polyomavirus and overall survival. Cancer Immunol Res 2013; 1(1): 54 - 63.

100. Schadendorf D., Nghiem P., Bhatia S. et al. Immune evasion mechanisms and immune checkpoint inhibition in advanced Merkel cell carcinoma. Oncoimmunology 2017; 6(10): e1338237.

101. Nghiem P.T., Bhatia S., Lipson E.J. et al. PD-1 blockade with pembrolizumab in advanced Merkel-cell carcinoma. N Engl J Med 2016; 374(26): 2542 - 52.

102. Topalian S.L., Bhatia S., Hollebecque A. et al. Non-comparative, open-label, multiple cohort, phase 1/2 study to evaluate nivolumab (NIVO) in patients with virus-associated tumors (CheckMate 358): efficacy and safety in Merkel cell carcinoma (MCC). Cancer Res 2017; 77(13 suppl): Abstract CT074.

103. Kaufman H.L., Russell J., Hamid O. et al. Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. Lancet Oncol 2016; 17(10): 1374 - 85.

104. Kaufman H.L., Russell J.S., Hamid O. et al. Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after 1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial. J Immunother Cancer 2018; 6: 7.

105. D'Angelo S.P., Russell J., C. et al. Efficacy and safety of first-line avelumab treatment in patients with stage IV metastatic Merkel cell carcinoma: a preplanned interim analysis of a clinical trial. JAMA Oncol 2018; 4(9): e180077. DOI: 10.1001/jamaoncol.2018.0077.

106. Nghiem P.T., Bhatia S., Lipson E.J. et al. Durable tumor regression and overall survival in patients with advanced merkel cell carcinoma receiving pembrolizumab as first-line therapy. J Clin Oncol 2019; 37(9): 693-702. DOI: 10.1200/JCO.18.01896.

107. Topalian S.L. et al. CT074: non-comparative, open-label, multiple cohort, phase 1/2 study to evaluate nivolumab (NIVO) in patients with virus-associated tumors (CheckMate 358): Efficacy and safety in Merkel cell carcinoma (MCC). Presented at: Annual Meeting of American Association for Cancer Research. April 1 - 5, 2017. Washington, DC.

108. Silver J.K., Baima J. Cancer prehabilitation: an opportunity to decrease treatment-related morbidity, increase cancer treatment options, and improve physical and psychological health outcomes. Am J Phys Med Rehabil 2013; 92(8): 715 - 27.

109. Nilsson H., Angeras U., Bock D. et al. Is preoperative physical activity related to post-surgery recovery? A cohort study of patients with breast cancer. BMJ Open 2016; 6(1): e007997.

110. Siegel G.W., Biermann J.S., Chugh R. et al. The multidisciplinary management of bone and soft tissue sarcoma: an essential organizational framework. J Multidiscip Health 2015; 8: 109 - 15.

111. Shehadeh A., El Dahleh M., Salem A. et al. Standardization of rehabilitation after limb salvage surgery for sarcomas improves patients' outcome. Hematol Oncol Stem Cell Ther 2013; 6(3 - 4): 105 - 11.

112. Marchese V.G., Spearing E., Callaway L. et al. Relationships among range of motion, functional mobility, and quality of life in children and adolescents after limb-sparing surgery for lower-extremity sarcoma. Pediatr Phys Ther 2006; 18(4): 238 - 44.

113. Cox C.L., Montgomery M., Oeffinger K.C. et al. Promoting physical activity in childhood cancer survivors: results from the Childhood Cancer Survivor Study. Cancer 2009; 115(3): 642 - 54.

114. Harvey L.A., Brosseau L., Herbert R.D. Continuous passive motion following total knee arthroplasty in people with arthritis. Cochrane Database Syst Rev 2014; (2): CD004260.

115. Field T. Massage therapy research review. Complement Ther Clin Pract 2016; 24: 19 - 31.

116. Tantawy S.A., Abdelbasset W.K., Nambi G., Kamel D.M. Comparative study between the effects of kinesio taping and pressure garment on secondary upper extremity lymphedema and quality of life following mastectomy: a randomized controlled trial. Integr Cancer Ther 2019; 18: 1534735419847276.

117. Fallon M., Giusti R., Aielli F. et al. Management of cancer pain in adult patients: ESMO Clinical Practice Guidelines. Ann Oncol 2018; 29 (Suppl 4): iv166 - 91.

118. Oren R., Zagury A., Katzir O. et al. Musculoskeletal cancer surgery. Ed.: Malawer. Dordrecht: Springer. 2013. Pp. 583 - 593.

119. Committee. NMA: Topic: The diagnosis and treatment of lymphedema. Position Statement of the National Lymphedema Network, 2011. Pp. 1 - 19.

120. Baxter G.D., Liu L., Petrich S. et al. Low level laser therapy (Photobiomodulation therapy) for breast cancer-related lymphedema: a systematic review. BMC Cancer 2017; 17(1): 833.

121. Segal R., Zwaal C., Green E. et al. Exercise for People with Cancer Guideline Development G: Exercise for people with cancer: a systematic review. Curr Oncol 2017; 24(4): e290 - 315.

122. Boyd C., Crawford C., Paat C.F. et al. The impact of massage therapy on function in pain populations - a systematic review and meta-analysis of randomized controlled trials: part II, cancer pain populations. Pain Med 2016; 17(8): 1553 - 68.

123. Stout N.L., Baima J., Swisher A.K. et al. A Systematic review of exercise systematic reviews in the cancer literature (2005 - 2017). PMR 2017; 9(9S2): S347 - 84.

124. Hu M., Lin W. Effects of exercise training on red blood cell production: implications for anemia. Acta Haematol 2012; 127(3): 156 - 64.

125. Mustian K.M., Alfano C.M., Heckler C. et al. Comparison of pharmaceutical, psychological, and exercise treatments for cancer-related fatigue: a meta-analysis. JAMA Oncol 2017; 3(7): 961 - 8.

126. Kinkead B., Schettler P.J., Larson E.R. et al. Massage therapy decreases cancer-related fatigue: results from a randomized early phase trial. Cancer 2018; 124(3): 546 - 54.

127. Streckmann F., Zopf E.M., Lehmann H.C. et al. Exercise intervention studies in patients with peripheral neuropathy: a systematic review. Sports Med 2014; 44(9): 1289 - 304.

128. Kleckner I.R., Kamen C., Gewandter J.S. et al. Effects of exercise during chemotherapy on chemotherapy-induced peripheral neuropathy: a multicenter, randomized controlled trial. Support Care Cancer 2018; 26(4): 1019 - 28.

129. Lee J.M., Look R.M., Turner C. et al. Low-level laser therapy for chemotherapy-induced peripheral neuropathy. J Clin Oncol 2012; 30(15_suppl): 9019.

130. Rick O., von Hehn U., Mikus E. et al. Magnetic field therapy in patients with cytostatics-induced polyneuropathy: a prospective randomized placebo-controlled phase-III study. Bioelectromagnetics 2017; 38(2): 85 - 94.

131. Kilinc M., Livanelioglu A., Yildirim S.A., Tan E. Effects of transcutaneous electrical nerve stimulation in patients with peripheral and central neuropathic pain. J Rehabil Med 2014; 46(5): 454 - 60.

132. Oberoi S., Zamperlini-Netto G., Beyene J. et al. Effect of prophylactic low level laser therapy on oral mucositis: a systematic review and meta-analysis. PLoS One 2014; 9(9): e107418.

133. Westphal J.G., Schulze P.C. Exercise training in cancer related cardiomyopathy. J Thorac Dis 2018; 10(Suppl 35): S4391 - 9.

134. Ross M., Fischer-Cartlidge E. Scalp cooling: a literature review of efficacy, safety, and tolerability for chemotherapy-induced alopecia. Clin J Oncol Nurs 2017; 21(2): 226 - 33.

135. Kessels E., Husson O., van der Feltz-Cornelis C.M. The effect of exercise on cancer-related fatigue in cancer survivors: a systematic review and meta-analysis. Neuropsychiatr Dis Treat 2018; 14: 479 - 94.

136. Rief H., Omlor G., Akbar M. et al. Feasibility of isometric spinal muscle training in patients with bone metastases under radiation therapy - first results of a randomized pilot trial. BMC Cancer 2014; 14: 67.

137. Bensadoun R.J., Nair R.G. Low-level laser therapy in the management of mucositis and dermatitis induced by cancer therapy. Photomed Laser Surg 2015; 33(10): 487 - 91.

138. Iyer J.G., Storer B.E., Paulson K.G. et al. Relationships among primary tumor size, number of involved nodes, and survival for 8044 cases of Merkel cell carcinoma. J Am Acad Dermatol 2014; 70(4): 637 - 43.

139. Gurney H: How to calculate the dose of chemotherapy. Br J Cancer 2002, 86(8): 1297 - 1302.

140. de Jongh F.E., Verweij J., Loos W.J., de Wit R., de Jonge M.J., Planting A.S., Nooter K., Stoter G., Sparreboom A.: Body-surface area-based dosing does not increase accuracy of predicting cisplatin exposure. J Clin Oncol 2001, 19(17): 3733 - 3739.

141. Temoshok L: Biopsychosocial studies on cutaneous malignant melanoma: psychosocial factors associated with prognostic indicators, progression, psychophysiology and tumor-host response. Soc Sci Med 1985, 20(8): 833 - 840.

142. Dirksen S.R.: Perceived well-being in malignant melanoma survivors. Oncol Nurs Forum 1989, 16(3): 353 - 358.

143. Lichtenthal W.G., Cruess D.G., Schuchter L.M., Ming M.E.: Psychosocial factors related to the correspondence of recipient and provider perceptions of social support among patients diagnosed with or at risk for malignant melanoma. J Health Psychol 2003, 8(6): 705 - 719.

144. Sollner W., Zschocke I., Zingg-Schir M., Stein B., Rumpold G., Fritsch P., Augustin M.: Interactive patterns of social support and individual coping strategies in melanoma patients and their correlations with adjustment to illness. Psychosomatics 1999, 40(3): 239 - 250.

145. Devine D., Parker P.A., Fouladi R.T., Cohen L.: The association between social support, intrusive thoughts, avoidance, and adjustment following an experimental cancer treatment. Psychooncology 2003, 12(5): 453 - 462.

146. Folkman S., Lazarus R.S., Gruen R.J., DeLongis A.: Appraisal, coping, health status, and psychological symptoms. J Pers Soc Psychol 1986, 50(3): 571 - 579.

147. Беляев А.М., Чулкова В.А., Семиглазова Т.Ю., Рогачев М.В. (eds.): Онкопсихология для врачей-онкологов и медицинских психологов. Руководство. СПб: Любавич; 2017.

148. Fawzy F.I., Cousins N., Fawzy N.W., Kemeny M.E., Elashoff R., Morton D.: A structured psychiatric intervention for cancer patients. I. Changes over time in methods of coping and affective disturbance. Arch Gen Psychiatry 1990, 47(8): 720 - 725.

149. Holland J.C., Passik S., Kash K.M., Russak S.M., Gronert M.K., Sison A., Lederberg M., Fox B., Baider L.: The role of religious and spiritual beliefs in coping with malignant melanoma. Psychooncology 1999, 8(1): 14 - 26.

150. Baider L., Perry S., Sison A., Holland J., Uziely B., DeNour A.K.: The role of psychological variables in a group of melanoma patients. An Israeli sample. Psychosomatics 1997, 38(1): 45 - 53.

151. Lehto U.S., Ojanen M., Kellokumpu-Lehtinen P.: Predictors of quality of life in newly diagnosed melanoma and breast cancer patients. Ann Oncol 2005, 16(5): 805 - 816.

152. McLoone J., Menzies S., Meiser B., Mann G.J., Kasparian N.A.: Psycho-educational interventions for melanoma survivors: a systematic review. Psychooncology 2013, 22(7): 1444 - 1456.

153. Kaufman H.L., Barbosa C.B. et al. Living with Merkel cell carcinoma (MCC): development of a conceptual model of MCC based on patient experiences. Patient. 2018; 11(4): 439 - 449.

154. Colgan M. B. et al. The predictive value of imaging studies in evaluating regional lymph node involvement in Merkel cell carcinoma//Journal of the American Academy of Dermatology. - 2012. - T. 67. - N 6. - C. 1250 - 1256.

155. Taralli S. et al. 18F-FDG and 68Ga-somatostatin analogs PET/CT in patients with Merkel cell carcinoma: a comparison study. EJNMMI Res 8, 64 (2018) doi: 10.1186/s13550-018-0423-3.

156. Guitera-Rovel P. et al. Indium-III octreotide scintigraphy of Merkel cell carcinomas and their metastases//Annals of oncology. - 2001. - T. 12. - N 6. - C. 807 - 811.

157. Kervarrec T. et al. Diagnostic accuracy of a panel of immunohistochemical and molecular markers to distinguish Merkel cell carcinoma from other neuroendocrine carcinomas//Modern Pathology. - 2019. - T. 32. - N 4. - C. 499.

158. Kervarrec T. at al. Differentiating Merkel cell carcinoma of lymph nodes without a detectable primary skin tumor from other metastatic neuroendocrine carcinomas: the ELECTHIP criteria. J Am Acad Dermatol. 2018; 78: 964 - 72.

159. Llombart, B., Monteagudo, C., Lopez-Guerrero, J. A., Carda, C., Jorda, E., Sanmartin, O., (2005). Clinicopathological and immunohistochemical analysis of 20 cases of Merkel cell carcinoma in search of prognostic markers. Histopathology, 46(6), 622 - 634. doi: 10.1111/j.1365-2559.2005.02158.

160. Panse G., McNiff J. M., Ko C. J. Basal cell carcinoma: CD56 and cytokeratin 5/6 staining patterns in the differential diagnosis with Merkel cell carcinoma//Journal of cutaneous pathology. - 2017. - T. 44. - N. 6. - C. 553 - 556.

161. Poulsen M.G. et al. Does chemotherapy improve survival in high-risk stage I and II Merkel cell carcinoma of the skin?//International Journal of Radiation Oncology* Biology* Physics. - 2006. - T. 64. - N. 1. - C. 114 - 119.

162. Meeuwissen, J. A., Bourne, R. G., & Kearsley, J. H. (1995). The importance of postoperative radiation therapy in the treatment of Merkel cell carcinoma. International Journal of Radiation Oncology*Biology*Physics, 31(2), 325 - 331. doi: 10.1016/0360-3016(94)e0145-a.

163. Hoeller U. et al. Regional nodal relapse in surgically staged Merkel cell carcinoma//Strahlentherapie und Onkologie. - 2015. - T. 191. - N 1. - C. 51 - 58.

164. Демидов Л.В. и соавторы, клинические рекомендации Министерства Здравоохранения. Карцинома Меркеля. [Электронный ресурс] Режим доступа: http://www.oncology.ru/association/clinical-guidelines/2018/karcinoma_merkelya_pr2018.pdf Дата доступа: 19.11.19

165. Loo B.W. et al. NCCN Guidelines Version 2.2020 Small cell Lung Cancer. https://www.nccn.org/professionals/physician_gls/pdf/sclc.pdf

166. Testa A. et al. Strengths of early physical rehabilitation programs in surgical breast cancer patients: results of a randomized control study//BMC proceedings. - BioMed Central, 2013. - T. 7. - N. 1. - C. 05.

167. Quist M. et al. Early initiated postoperative rehabilitation reduces fatigue in patients with operable lung cancer: A randomized trial//Lung Cancer. - 2018. - T. 126. - C. 125 - 132.

168. Perez M. C. et al. Resection Margins in Merkel Cell Carcinoma: Is a 1-cm Margin Wide Enough?//Annals of surgical oncology. - 2018. - T. 25. - N. 11. - C. 3334 - 3340.

169. Mattavelli I. et al. Prognostic factors in Merkel cell carcinoma patients undergoing sentinel node biopsy//European Journal of Surgical Oncology (EJSO). - 2017. - T. 43. - N. 8. - C. 1536 - 1541.

170. Stout N.L. et al. A systematic review of exercise systematic reviews in the cancer literature (2005 - 2017). PM R. 2017 Sep; 9(9S2): S347 - S384.

171. Smoller B.R., Bichakjian C., Brown J.A., Crowson A.N., Divaris D., Frishberg D.P. et al. Protocol for the Examination of Specimens from Patients with Merkel Cell Carcinoma of the Skin. Version: Merkel Cell 4.0.0.1. USA: College of American Pathologists, 2017.

172. Slater D., Ali R. Standarts and datasets for reporting cancers. Dataset for histological reporting of primary cutaneous Merkel cell carcinoma and regional lymph nodes. February 2019. V.5. [Электронный ресурс] Режим доступа: https://www.rcpath.org/uploads/assets/cd3d3fab-eab2-43e4-8d9fec9c5d55fd7a/Dataset-for-the-histological-reporting-of-primary-cutaneous-Merkel-cell-carcinoma-and-regional-lymph-nodes.pdf.